Linked Life Data

22013544

Source:http://linkedlifedata.com/resource/pubmed/id/22013544

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2011-10-20
pubmed:abstractText
Purpose. Determine patient-reported reasons for discontinuation with teriparatide. Methods. Patients taking teriparatide in a multicenter, prospective, and observational study were given three questionnaires: baseline, follow-up questionnaire 1 (QF1, 2 to 6 months), and follow-up questionnaire 2 (QF2, 12 months). Discontinuation reported at QF1 and QF2 was defined as "early" and "late," respectively, and remaining patients were considered persistent. Cochran-Armitage trend test was used to identify factors associated with discontinuation. Results. Side effects, concern about improper use, injection difficulties, and several patient-perceived physician issues were associated with early discontinuation. Low patient-perceived importance of continuing treatment, side effects, difficulty paying, and low patient-perceived physician knowledge were associated with late discontinuation. The most common specific reasons selected for discontinuing treatment were "concerns about treatment outweighing the benefits" (n = 53) and "difficulty paying" (n = 47). Conclusions. Persistence with teriparatide is dependent on managing side effects, addressing financial challenges, proper training, and obtaining support from the healthcare provider.
pubmed:language
eng
pubmed:journal
pubmed:status
PubMed-not-MEDLINE
pubmed:issn
2042-0064
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
2011
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
314970
pubmed:year
2011
pubmed:articleTitle
Factors Associated with Persistence with Teriparatide Therapy: Results from the DANCE Observational Study.
pubmed:affiliation
Departments of Psychiatry and Behavioral Sciences, Sociology, and Psychology and Neuroscience, Duke University Medical Center, Durham, NC 27710, USA.
pubmed:publicationType
Journal Article